New insights in sarcoma oncogenesis: A comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics

Journal of Pathology

Volumn 223, Issue 1, 2011, Pages 64-71

  Gibault, Laure ^a,b,c,d   Pérot, Gaẽlle ^a,b   Chibon, Frédéric ^e   Bonnin, Sarah ^a,b   Lagarde, Pauline ^e   Terrier, Philippe ^f   Coindre, Jean Michel ^e   Aurias, Alain ^a,b  

^a INSTITUT CURIE   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Cochin Hospital ^*  (France)

^e INSTITUT BERGONIÉ   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

CGH; DKK1; leiomyosarcoma; PTEN; RB1; transcriptome; undifferentiated sarcoma

Indexed keywords

DICKKOPF 1 PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE DEACETYLASE 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LRRFIP1 PROTEIN; MYOCARDIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN P130; RETINOBLASTOMA PROTEIN; T CELL FACTOR PROTEIN; TRANSCRIPTOME; TRIO PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CHROMOSOME 10Q; CHROMOSOME 15P; CHROMOSOME 16Q; CHROMOSOME 1Q; CHROMOSOME 2Q; CHROMOSOME DELETION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE AMPLIFICATION; GENE CLUSTER; GENETIC ANALYSIS; GENOMICS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; TUMOR DIFFERENTIATION; UPREGULATION;

ADULT; AGED; CELL TRANSFORMATION, NEOPLASTIC; CLUSTER ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE DELETION; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEIOMYOSARCOMA; MALE; MIDDLE AGED; PTEN PHOSPHOHYDROLASE; RETINOBLASTOMA PROTEIN; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 78650000822     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2787     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, et al., Cancer statistics. CA Cancer J Clin 2009; 59: 225-249.
2. Fletcher CD, Unni KK, Mertens F,. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone (3rd edn). IARC Press: Lyon, 2002.
3. Turc-Carel C, Dal Cin P, Limon J, et al., Translocation X;18 in synovial sarcoma. Cancer Genet Cytogenet 1986; 23: 93.
4. Chibon F, Mariani O, Derré J, et al., A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas. Cancer Genet Cytogenet 2002; 139: 24-29.
5. Coindre JM, Mariani O, Chibon F, et al., Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol 2003; 16: 256-262.
6. Derré J, Lagacé R, Nicolas A, et al., Leiomyosarcomas and most malignant fibrous histiocytomas share very similar comparative genomic hybridization imbalances: an analysis of a series of 27 leiomyosarcomas. Lab Invest 2001; 81: 211-215.
7. Fletcher CD,. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 2006; 48: 3-12.
8. Weichselbaum RR, Beckett M, Diamond A,. Some retinoblastomas, osteosarcomas, and soft tissue sarcomas may share a common etiology. Proc Natl Acad Sci U S A 1988; 85: 2106-2109.
9. Chibon F, Mairal A, Fréneaux P, et al., The RB1 gene is the target of chromosome 13 deletions in malignant fibrous histiocytoma. Cancer Res 2000; 60: 6339-6345.
10. Hernando E, Charytonowicz E, Dudas ME, et al., The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nature Med 2007; 13: 748-753.
11. Glinka A, Wu W, Delius H, et al., Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998; 391: 357-362.
12. Matushansky I, Hernando E, Socci ND, et al., Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest 2007; 117: 3248-3257.
13. Trojani M, Contesso G, Coindre JM, et al., Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984; 33: 37-42.
14. Guillou L, Coindre JM, Bonichon F, et al., Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997; 15: 350-362.
15. Coindre JM, Terrier P, Guillou L, et al., Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001; 91: 1914-1926.
16. Pérot G, Derré J, Coindre JM, et al., Strong smooth muscle differentiation is dependent on myocardin gene amplification in most human retroperitoneal leiomyosarcomas. Cancer Res 2009; 69: 2269-2278.
17. Wu Z, Irizarry RA, Gentleman R, et al., A model based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 2004; 99: 909-917.
18. Greenacre M,. Correspondence analysis in medical research. Stat Methods Med Res 1992; 1: 97-117.
19. Vincent-Salomon A, Gruel N, Lucchesi C, et al., Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007; 9: R24.
20. La Rosa P, Viara E, Hupé P, et al., VAMP: visualization and analysis of array-CGH, transcriptome and other molecular profiles. Bioinformatics 2006; 22: 2066-2073.
21. Du KL, Ip HS, Li J, et al., Myocardin is a critical serum response factor cofactor in the transcriptional program regulating smooth muscle cell differentiation. Mol Cell Biol. 2003; 23: 2425-2437.
22. Badorff C, Seeger FH, Zeiher AM, et al., Glycogen synthase kinase 3beta inhibits myocardin-dependent transcription and hypertrophy induction through site-specific phosphorylation. Circ Res 2005; 97: 645-654.
23. Guo Y, Xie J, Rubin E, et al., Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling. Cancer Res 2008; 68: 3350-3360.
24. Glenisson W, Castronovo V, Waltregny D,. Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation. Biochim Biophys Acta 2007; 1773: 1572-1582.
25. Yoshida T, Gan Q, Shang Y, et al., Platelet-derived growth factor-BB represses smooth muscle cell marker genes via changes in binding of MKL factors and histone deacetylases to their promoters. Am J Physiol Cell Physiol 2007; 292: C886-C895.
26. Regamey A, Hohl D, Liu JW, et al., The tumour suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumour necrosis factor. J Exp Med 2003; 198: 1959-1964.
27. Suriano AR, Sanford AN, Kim N, et al., GCF2/LRRFIP1 represses tumour necrosis factor alpha expression. Mol Cell Biol 2005; 25: 9073-9081.
28. Adamowicz M, Radlwimmer B, Rieker RJ, et al., Frequent amplifications and abundant expression of TRIO, NKD2, and IRX2 in soft tissue sarcomas. Genes Chromosomes Cancer 2006; 45: 829-838.
29. Mhawech-Fauceglia P, Cheney RT, Schwaller J,. Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer 2006; 106: 1205-1216.
30. Kloth JN, Oosting J, van Wezel T, et al., Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer. BMC Genomics 2007; 8: 53-66.
31. Bellanger JM, Lazaro JB, Diriong S, et al., The two guanine nucleotide exchange factor domains of Trio link the Rac1 and the RhoA pathways in vivo. Oncogene 1998; 16: 147-152.
32. Bellanger JM, Astier C, Sardet C, et al., The Rac1- and RhoG-specific GEF domain of Trio targets filamin to remodel cytoskeletal actin. Nature Cell Biol 2000; 2: 888-892.
33. Blangy A, Vignal E, Schmidt S, et al., TrioGEF1 controls Rac- and Cdc42-dependent cell structures through the direct activation of rhoG. J Cell Sci 2000; 113: 729-739.
34. Jiang BH, Liu LZ,. PI3K/PTEN signaling in angiogenesis and tumourigenesis. Adv Cancer Res 2009; 102: 19-65.
35. Classon M, Salama S, Gorka C, et al., Combinatorial roles for pRB, p107, and p130 in E2F-mediated cell cycle control. Proc Natl Acad Sci U S A 2000; 97: 10820-10825.
36. De Falco G, Giordano A,. pRb2/p130: a new candidate for retinoblastoma tumour formation. Oncogene 2006; 25: 5333-5340.
37. Priya K, Jada SR, Quah BL, et al., High incidence of allelic loss at 16q12.2 region spanning RBL2/p130 gene in retinoblastoma. Cancer Biol Ther 2009; 8: 714-717.
38. Larramendy ML, Gentilec M, Soloneskib S, et al., Does comparative genomic hybridization reveal distinct differences in DNA copy number sequence patterns between leiomyosarcoma and malignant fibrous histiocytoma? Cancer Genet Cytogenet 2008; 187: 1-11.
39. Nielsen TO, West RB, Linn SC, et al., Molecular characterization of soft tissue tumours: a gene expression study. Lancet 2002; 359: 1301-1307.
40. Lee YF, John M, Edwards S, et al., Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. Br J Cancer 2003; 88: 510-515.
41. Baird K, Davis S, Antonescu CR, et al., Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 2005; 65: 9226-9235.
42. Francis P, Namlos HM, Muller C, et al., Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 2007; 8: 73.
43. Nakayama R, Nemoto T, Takahashi H, et al., Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol 2007; 20: 749-759.
44. Beck AH, Lee CH, Witten DM, et al., Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. Oncogene 2010; 29: 845-854.
45. Carneiro A, Francis P, Bendahl PA, et al., Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: different sides of a single coin? Lab Invest 2009; 89: 668-675.
46. Chibon F, Lagarde P, Salas S, et al., Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nature Med 2010; 16: 781-787.
47. Qiang YW, Barlogie B, Rudikoff S, et al., Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone 2008; 42: 669-680.